Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 466

Sort by

Sort Order Select

Journal Articles

Tracing the roots of CLPD-NK by TET2 and STAT3

Marco Herling, Till Braun

Blood (2021) 137 (23): 3156–3158.

https://doi.org/10.1182/blood.2020010542

Published: 2021

Journal Articles

Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells

Cédric Pastoret, Fabienne Desmots, Gaëlle Drillet, Simon Le Gallou, Marie-Laure Boulland, Alexia Thannberger, Anne-Violaine Doncker, Véronique Salaun, Gandhi Laurent Damaj, Richard Veyrat-Masson, Olivier Tournilhac, Aline Moignet, Céline Pangault, Mikaël Roussel, Thierry Fest, Thierry Lamy

Blood (2021) 137 (23): 3237–3250.

https://doi.org/10.1182/blood.2020006721

Published: 2021

Includes: Supplemental data

Journal Articles

Modeling and targeting of erythroleukemia by hematopoietic genome editing

Blood (2021) 137 (12): 1628–1640.

https://doi.org/10.1182/blood.2020009103

Published: 2021

Includes: Supplemental data

Journal Articles

Human TET2 bridges cancer and immunity

Qian Zhang, Jean-Laurent Casanova

Blood (2020) 136 (9): 1018–1019.

https://doi.org/10.1182/blood.2020006881

Published: 2020

Journal Articles

Germline TET2 loss of function causes childhood immunodeficiency and lymphoma

Blood (2020) 136 (9): 1055–1066.

https://doi.org/10.1182/blood.2020005844

Published: 2020

Includes: Supplemental data

Journal Articles

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

Blood (2020) 136 (6): 698–714.

https://doi.org/10.1182/blood.2019003062

Published: 2020

Includes: Supplemental data

Journal Articles

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Huthayfa Mujahed, Sophia Miliara, Anne Neddermeyer, Sofia Bengtzén, Christer Nilsson, Stefan Deneberg, Lina Cordeddu, Karl Ekwall, Andreas Lennartsson, Sören Lehmann

Blood (2020) 136 (3): 339–352.

https://doi.org/10.1182/blood.2019002326

Published: 2020

Includes: Supplemental data

Journal Articles

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Blood (2019) 134 (Supplement_1): 3720.

https://doi.org/10.1182/blood-2019-129276

Published: 2019

Journal Articles

Hmga2 Functions As an Oncogene upon the Deletion of Tet2 and Promotes the Pathogenesis of Myelodysplastic Syndrome

Jie Bai, Sho Kubota, PhD, Takako Yokomizo, PhD, Akinori Kanai, PhD, Yuqi Sun, MD, Mihoko Iimori, CLS, Hironori Harada, MD PhD, Naomi Nakagata, PhD, Atsushi Iwama, MD PhD, Goro Sashida, MD PhD

Blood (2019) 134 (Supplement_1): 3782.

https://doi.org/10.1182/blood-2019-127583

Published: 2019

Journal Articles

Combined Heterozygous Loss of Tet2 and Dnmt3a Along with Expression of Flt3 ITD/WT results in Acute Myeloid Leukemia Which Responds to a Combination of FLT3 Inhibitor, APE1 Inhibitor and Decitabine

Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Raghuveer Singh Mali, PhD, Zhigang Cai, PhD, Ruchi Pandey, PhD, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 3754.

https://doi.org/10.1182/blood-2019-131172

Published: 2019

Journal Articles

Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of TET2 Mutant AML

Ellie Wilson, BS, Nichole Helton, Catrina Fronick, BS, Robert Fulton, MS, John S. Welch, MD PhD, Timothy J Ley, MD, David H Spencer, MD

Blood (2019) 134 (Supplement_1): 3755.

https://doi.org/10.1182/blood-2019-122340

Published: 2019

Journal Articles

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

Blood (2019) 134 (Supplement_1): 2472.

https://doi.org/10.1182/blood-2019-129056

Published: 2019

Journal Articles

Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Hassan Awada, MD, Shafia Rahman, MBBS, Cassandra M Kerr, MS, Jibran Durrani, Vera Adema, PhD, Ashwin Kishtagari, MBBS, Sunisa Kongkiatkamon, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 2499.

https://doi.org/10.1182/blood-2019-131918

Published: 2019

Journal Articles

Recurrent Gene Mutations in Pediatric Patients with AML By Targeted Sequencing ―the Jccg Study, JPLSG AML-05―

Blood (2019) 134 (Supplement_1): 2697.

https://doi.org/10.1182/blood-2019-126545

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Sebastian Vosberg, Paul Kerbs, MSc, Vindi Jurinovic, MSc, Klaus H. Metzeler, MD, Susanne Amler, PhD, Cristina Sauerland, Dennis Görlich, PhD, Wolfgang E. Berdel, MD, Jan Braess, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD, Philipp A. Greif, MD PD

Blood (2019) 134 (Supplement_1): 2715.

https://doi.org/10.1182/blood-2019-130047

Published: 2019

Journal Articles

Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Sanghee Hong, MD, Cassandra M Kerr, MS, Lisa Rybicki, MS, Valeria Visconte, PhD, Jibran Durrani, Hassan Awada, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Aaron T. Gerds, MD MS, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, MD, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2716.

https://doi.org/10.1182/blood-2019-130352

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Blood (2019) 134 (Supplement_1): 3005.

https://doi.org/10.1182/blood-2019-124115

Published: 2019

Journal Articles

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Venkata Thammineni, MD, Terrence J Bradley, MD, Felipe Novoa, NP, Deukwoo Kwon, Justin M. Watts, MD

Blood (2019) 134 (Supplement_1): 5107.

https://doi.org/10.1182/blood-2019-131006

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Tracing the roots of CLPD-NK by TET2 and STAT3

Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells

Modeling and targeting of erythroleukemia by hematopoietic genome editing

Human TET2 bridges cancer and immunity

Germline TET2 loss of function causes childhood immunodeficiency and lymphoma

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Hmga2 Functions As an Oncogene upon the Deletion of Tet2 and Promotes the Pathogenesis of Myelodysplastic Syndrome

Combined Heterozygous Loss of Tet2 and Dnmt3a Along with Expression of Flt3 ITD/WT results in Acute Myeloid Leukemia Which Responds to a Combination of FLT3 Inhibitor, APE1 Inhibitor and Decitabine

Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of TET2 Mutant AML

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Recurrent Gene Mutations in Pediatric Patients with AML By Targeted Sequencing ―the Jccg Study, JPLSG AML-05―

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only